Emily Estrada

MRI-adapted RECIST criteria improved response assessment compared to RECIST 1.1 following percutaneous cryoablation in patients with progressing extra-abdominal desmoid-type fibromatosis.

Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly improved progression-free survival compared with placebo in patients with progressive desmoid tumors.

The longest reported follow-up of enfortumab vedotin plus pembrolizumab demonstrated durable long-term survival and sustained clinical benefit in

Results from the phase 2 IMGN853-0420 trial demonstrated that mirvetuximab soravtansine plus carboplatin remained active patients with FRα-positive recurrent platinum-sensitive ovarian cancer, regardless of PARP inhibitor exposure.

Results from the phase 3 PrTK03 trial demonstrated that adding aglatimagene besadenovec plus valacyclovir to standard external-beam radiotherapy

The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...

The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.

On July 10, 2026, the US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase (Keytruda

Results from the phase 3 EPO-PRETAR trial demonstrated that early initiation of epoetin alfa did not delay progression to transfusion dependence in

Results from the phase 3b MAXILUS trial demonstrated that luspatercept initiated at the maximum approved dose produced durable erythroid responses